MDWD
MediWound Ltd
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
mediwound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. mediwound’s first innovative biopharmaceutical product, nexobrid®, received marketing authorization from the european medicines agency as well as the israeli and argentinian ministries of health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in europe israel and argentina. nexobrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and without harming viable tissue. mediwound's second innovative product, escharex®, is a topical biological drug being developed for debridement of chronic and
Market Cap: 212 Million
Primary Exchange: NASDAQ
Website: http://www.mediwound.com
Shares Outstanding: 12.8 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.5560317862089426
Sector: Manufacturing
Industry: Medicinal and Botanical Manufacturing
Ethical Flags
Longest drawdown: 2855 trading days
From: 2014-03-21 To: 2024-03-07
Lowest Point:
Target Acquired: The NexoBrid Acquisition And Its Implications For Vericel
via: SeekingAlpha at 2019-06-10 04:41:34:000
For a year, Vericel ( VCEL ) teased investors with hints that it would be adding an acquisition to its product line. After doing a large, surprise secondary offering of $75 million in June 2018, Vericel indicated it was actively on the hunt for " commercial products or businesses which would … read more...
Target Acquired: The NexoBrid Acquisition And Its Implications For Vericel
via: SeekingAlpha at 2019-06-10 04:41:34:000
For a year, Vericel ( VCEL ) teased investors with hints that it would be adding an acquisition to its product line. After doing a large, surprise secondary offering of $75 million in June 2018, Vericel indicated it was actively on the hunt for " commercial products or businesses which would … read more...
Target Acquired: The NexoBrid Acquisition And Its Implications For Vericel
via: SeekingAlpha at 2019-06-10 04:41:34:000
For a year, Vericel ( VCEL ) teased investors with hints that it would be adding an acquisition to its product line. After doing a large, surprise secondary offering of $75 million in June 2018, Vericel indicated it was actively on the hunt for " commercial products or businesses which would … read more...
Target Acquired: The NexoBrid Acquisition And Its Implications For Vericel
via: SeekingAlpha at 2019-06-10 04:41:34:000
For a year, Vericel ( VCEL ) teased investors with hints that it would be adding an acquisition to its product line. After doing a large, surprise secondary offering of $75 million in June 2018, Vericel indicated it was actively on the hunt for " commercial products or businesses which would … read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|